Word: biotechs
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...though they've been penalized for sitting on the sidelines in money-market accounts earning 3%. "When they feel penalized, then the first stop into the equity market is the large-cap multinational company," he says. "You don't come off the sidelines and go to some small biotech company whose name you don't even know...
Despite fears expressed by many scientists that they would have to pay dearly to work on stem cells, officials at WARF are echoing Freire's sentiments. The foundation has licensed the Menlo Park, Calif., biotech firm Geron to commercialize six specific cell types derived from Thomson's five primary stem-cell lines--though it is fighting the company's attempt to extend that license to 12 more derived types...
...into the tissue of a laboratory animal. Researchers had already tried encasing large molecules like the one Langer was testing in polymers (long-chain molecules, such as silicone, that are semipermeable to certain types of molecules). Unfortunately, this particular molecule--like most of the new drugs being created in biotech labs--was much too large to fit through the tiny holes in any of the available polymers. The problem, polymer experts told Langer, was unsolvable...
...contrast, two other groups chose a more provocative path. In July of this year, the Jones Institute for Reproductive Medicine in Norfolk, Va., made headlines by announcing that it had created embryos (from donated sperm and eggs) expressly to extract their stem cells. A few days later, a Massachusetts biotech firm, Advanced Cell Technology, disclosed that it was trying to create embryos using human-cloning techniques. The back-to-back developments surprised opponents and supporters alike, and brought new calls for a ban on all embryonic stem-cell research...
...fanfare, Thomson set himself up six years ago in an off-campus lab under a nonprofit arrangement with the University of Wisconsin's alumni association. That way he freed himself from existing federal restrictions--and avoided jeopardizing the university's government-funded research. Geron Corp., the Menlo Park, Calif., biotech firm that was financing Gearhart's efforts, partly bankrolled Thomson's work in exchange for commercial rights. (Thomson, however, was free to distribute his stem cells to fellow academics.) Because he could afford only one part-time assistant, he ended up doing much of the work himself, getting...